Moxidectin, Oxfendazole, Levamisole HCL Water Based Formulation

 Version
 Revision Date
 Date of First Issue
 Date of Last Issue

 2.0
 18-04-2023
 23-06-2021
 18-04-2023

Section 1: Identification

Product name: Cervidae Oral

Manufacturer Details

Company: Nexan Corporation Limited

Address: 16A Ormiston Road, East Tamaki, Auckland, New Zealand.

Telephone: 09 274 8848

Emergency telephone number: 0800 764 766 (0800 POISON)

Recommended use of the Product

Recommended use: Veterinary Medicine

Section 2: Hazard Identification

GHS Classification

Skin sensitisation: Category 1
Germ cell mutagenicity: Category 2
Reproductive toxicity: Category 1

Reproductive toxicity: Effects on or via lactation

Specific target organ toxicity single exposure: Category 2 Specific target organ toxicity repeated exposure: Category 2 Hazardous to the aquatic environment acute: Category 1 Hazardous to the aquatic environment chronic: Category 1

Hazardous to soil organisms

Hazardous to terrestrial invertebrates

GHS label elements

Hazard pictograms:







Signal Word: Warning

Hazard statements: H317 May cause an allergic skin reaction.

H341 Suspected of causing genetic defects. H360 May damage fertility or the unborn child H362 May cause harm to breast-fed children.

H371 May cause damage to organs

H373 May cause damage to organs through prolonged or repeated

exposure

H400 Very toxic to aquatic life.

H410 Very toxic to aquatic life with long lasting effects.

H423 Harmful to the soil environment.

Moxidectin, Oxfendazole, Levamisole HCL Water Based Formulation

Version Revision Date 2.0 18-04-2023

Date of First Issue 23-06-2021

Date of Last Issue 18-04-2023

H443 Harmful to terrestrial invertebrates.

Precautionary statements:

Prevention:

P103 Read label before use.

P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read and understood.

P260 Do not breathe dust/fume/gas/mist/vapours/spray

P261 Avoid breathing dust/fume/gas/mist/vapours/spray.

P263 Avoid contact during pregnancy/while nursing.

P264 Wash hands thoroughly after handling.

P270 Do not eat, drink or smoke when using this product.

P272 Contaminated work clothing should not be allowed out of the workplace.

P273 Avoid release to the environment.

P280 Wear protective gloves/protective clothing/eye protection/face protection.

P281 Use personal protective equipment as required.

Response:

P101 If medical advice is needed, have product container or label at hand.

P302 IF ON SKIN: P352 Wash with plenty of soap and water.

P308 IF exposed or concerned: P313 Get medical advice/attention.

P312 Call a POISON CENTER or doctor/physician if you feel unwell.

P314 Get medical advice/attention if you feel unwell.

P321 Specific measures in section 4.

P322 Specific measures in section 4.

P333 f skin irritation or rash occurs: P313 Get medical advice/attention.

P363 Wash contaminated clothing before reuse.

P391 Collect spillage.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

None known.

Moxidectin, Oxfendazole, Levamisole HCL Water Based Formulation

 Version
 Revision Date
 Date of First Issue
 Date of Last Issue

 2.0
 18-04-2023
 23-06-2021
 18-04-2023

Section 3: Compositon/information on ingredients

Substance / Mixture: Mixture

Components

Chemical name	CAS number	Concentration (% w/v)
Moxidectin	113507-06-5	0.4
Levamisole HCL	16595-80-5	12.0
Oxfendazole	53716-50-0	18.0
Citric acid	77-92-9	<10

Section 4: First-aid measures

General advice: In the case of accident or if you feel unwell, seek medical advice

immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled: If inhaled, remove to fresh air.

Get medical attention if symptoms occur.

In case of skin contact: In case of contact, immediately flush skin with soap and plenty of water.

Get medical attention if symptoms occur.

In case of eye contact: Flush eyes with water as a precaution.

Get medical attention if irritation develops and persists.

Causes damage to organs through prolonged or repeated

If swallowed: If swallowed, DO NOT induce vomiting.

Get medical attention if symptoms occur.

Rinse mouth thoroughly with water.

Most important symptoms

and effects, both acute and

delayed:

exposure.

Protection of first-aiders: First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment

when the potential for exposure exists (see section 8).

Notes to physician: Treat symptomatically and supportively.

Section 5: Fire-fighting measures

Suitable extinguishing media: Water spray

Alcohol-resistant foam Carbon dioxide (CO₂)

Dry chemical

Unsuitable extinguishing media: None known.

Specific hazards during firefighting: Exposure to combustion products may be a hazard to health.

Hazardous combustion products: Nitrogen oxides (NOx)

Carbon oxides

Specific extinguishing methods: Use extinguishing measures that are appropriate to local circumstances and

the surrounding environment.

Use water spray to cool unopened containers.

Moxidectin, Oxfendazole, Levamisole HCL Water Based Formulation

Version **Revision Date** Date of First Issue Date of Last Issue 2.0 18-04-2023 23-06-2021 18-04-2023

Remove undamaged containers from fire area if it is safe to do so.

Special protective equipment:

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

Section 6: Accidental release measures

Personal precautions, protective

equipment and emergency

procedures:

Environmental precautions:

Methods and materials for containment and cleaning up: Use personal protective equipment.

Follow safe handling advice (see section 7) and personal protective

equipment recommendations (see section 8).

Avoid release to the environment.

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages cannot be

contained.

Soak up with inert absorbent material.

For large spills, provide dyking or other appropriate containment to keep

material from spreading. If dyked material can be pumped, store recovered

material in appropriate container.

Clean up remaining materials from spill with suitable absorbent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding certain local or

national requirements.

Section 7: Handling and storage

Technical measures: See Engineering measures under section 8.

Local/Total ventilation: Use only with adequate ventilation.

Advice on safe handling: Do not breathe dust, fume, gas, mist, vapours or spray.

Do not swallow.

Avoid contact with eyes.

Avoid prolonged or repeated contact with skin.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice,

based on the results of the workplace exposure assessment

Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the environment.

If exposure to chemical is likely during typical use, provide eye flushing Hygiene measures:

systems and safety showers close to the working place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical

surveillance and the use of administrative controls.

Conditions for safe storage: Keep in properly labelled containers.

Moxidectin, Oxfendazole, Levamisole HCL Water Based Formulation

 Version
 Revision Date
 Date of First Issue
 Date of Last Issue

 2.0
 18-04-2023
 23-06-2021
 18-04-2023

Store in accordance with the particular national regulations.

Materials to avoid: Do not store with the following product types:

Strong oxidizing agents

Section 8: Exposure controls/personal protection

Components with workplace control parameters

No WES is set for this substance at this time.

Engineering measures: Use feasible engineering controls to minimize exposure to compound.

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers,

and the environment.

Personal protective equipment

Respiratory protection: If adequate local exhaust ventilation is not available or exposure assessment

demonstrates exposures outside the recommended guidelines, use

respiratory protection.

Filter type: Organic vapour type

Hand protection Material: Chemical-resistant gloves

Eye protection: Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions, mists or

aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for

direct contact to the face with dusts, mists, or aerosols.

Skin and body protection: Work uniform or laboratory coat.

Section 9: Physical and chemical properties

Appearance: Aqueous suspension

Colour: White liquid Specific gravity: 1.06 - 1.12

Behaviour in water: Miscible in water

Moxidectin, Oxfendazole, Levamisole HCL Water Based Formulation

 Version
 Revision Date
 Date of First Issue
 Date of Last Issue

 2.0
 18-04-2023
 23-06-2021
 18-04-2023

Section 10: Stability and reactivity

Reactivity: Not classified as a reactivity hazard. Chemical stability: Stable under normal conditions.

Possibility of hazardous reactions: Can react with strong oxidizing agents.

Conditions to avoid: None known. Incompatible materials: Oxidizing agents

Hazardous decomposition products: No hazardous decomposition products are known.

Section 11: Toxicological information

Inhalation: Harmful if inhaled Ingestion: Harmful if swallowed Moxidectin: LD50 842 mg/kg Levamisole: LD50 200mg/kg/bw Citric acid: LD50 5000mg/kg/bw Skin: Citric acid – Irritating

Chronic Effects

Levamisole: Mutagenic effects.

Moxidectin: No evidence of mutagenic or carcinogenic effects. Oxfendazole: NOAEL 20mg/kg/bw/day for reproductive effects

Section 12: Ecological information

Aquatic: Moxidectin: 96hr LC50 0.16ppb (Rainbow trout)

Oxfendazole: 48hr LC50 0.52mg/L (Daphnia magna)

Soil: Moxidectin: DT50>30days

Terrestrial Vertebrates: Moxidectin: 42mg/kg

Levamisole: LD50 200mg/kg/bw

Terrestrial Invertebrates: Moxidectin: LD50 0.025ug/bee

Section 13: Disposal considerations

Disposal methods

Waste from residues: Dispose of in accordance with local regulations.

Contaminated packaging: Empty containers should be taken to an approved waste handling site for

recycling or disposal.

If not otherwise specified: Dispose of as unused product.

Moxidectin, Oxfendazole, Levamisole HCL Water Based Formulation

 Version
 Revision Date
 Date of First Issue
 Date of Last Issue

 2.0
 18-04-2023
 23-06-2021
 18-04-2023

Section 14: Transport information

Dangerous Goods for transport. ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Moxidectin)

DG Class: 9

UN Number: 3082

Section 15: Regulatory information

Safety, health and environmental regulations/legislation specific for the substance or mixture

HSNO Approval Number

HSR100758 Veterinary Medicines Non dispersive Closed System Application Group Standard 2020

HSW Controls

Certified handler certificate not required.

Tracking hazardous substance not required.

Refer to the Health and Safety at Work (Hazardous Substances) Regulations 2017, for further information.

Section 16: Other information

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.